Guselkumab Ranked Highest Overall in Skin Clearance with Philip Mease, MD
January 31, 202218m 42s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Last week, Janssen announced results from a network meta-analysis (NMA) that showed that the biologic therapy guselkumab ranked highest for overall level of skin clearance. The NMA involved 33 phase 3 randomized clinical trials and 15 different targeted therapies including risakinumab and more.
Philip J. Mease, MD, director of rheumatology research at the Swedish Rheumatology Research Group, spoke of how the biologic distinguished itself from other targeted therapies in the network meta-analyses, and how these kinds of analyses could aid physicians in treating patients affected by psoriasis.
Philip J. Mease, MD, director of rheumatology research at the Swedish Rheumatology Research Group, spoke of how the biologic distinguished itself from other targeted therapies in the network meta-analyses, and how these kinds of analyses could aid physicians in treating patients affected by psoriasis.